A review of vagus nerve stimulation as a therapeutic intervention.
A review of vagus nerve stimulation as a therapeutic intervention.
复制标题
DOI：
10.2147/jir.s163248
复制
发表时间：
2018
影响因子：
4.5
通讯作者：
Wilson CG
中科院分区：
文献类型：
--
作者：
Johnson RL;Wilson CG
在这篇综述中，我们概述了美国食品药品监督管理局（FDA）批准的迷走神经刺激（VNS）的临床用途，以及正在进行的研究和临床前研究的信息，以扩大VNS的使用到其他应用。VNS目前被FDA批准用于治疗年龄>12岁的耐药性癫痫和抑郁症患者。VNS在体内系统中的最新研究表明，它具有抗炎特性，这导致了更多的临床前研究，旨在将VNS治疗扩展到更广泛的炎症性疾病。虽然VNS影响炎症的信号通路和机制仍然未知，但VNS在治疗慢性炎症性疾病如败血症、肺损伤、类风湿性关节炎（RA）和糖尿病方面显示出有希望的结果。它也被用来控制纤维肌痛和偏头痛的疼痛。这项新的临床前研究表明，VNS有望应用于更广泛的治疗应用。
In this review, we provide an overview of the US Food and Drug Administration (FDA)-approved clinical uses of vagus nerve stimulation (VNS) as well as information about the ongoing studies and preclinical research to expand the use of VNS to additional applications. VNS is currently FDA approved for therapeutic use in patients aged >12 years with drug-resistant epilepsy and depression. Recent studies of VNS in in vivo systems have shown that it has anti-inflammatory properties which has led to more preclinical research aimed at expanding VNS treatment across a wider range of inflammatory disorders. Although the signaling pathway and mechanism by which VNS affects inflammation remain unknown, VNS has shown promising results in treating chronic inflammatory disorders such as sepsis, lung injury, rheumatoid arthritis (RA), and diabetes. It is also being used to control pain in fibromyalgia and migraines. This new preclinical research shows that VNS bears the promise of being applied to a wider range of therapeutic applications.